

INDEX 1988 VA PRACTITIONER

SUBJECT INDEX

AIDS

AIDS and the VA: A report from the front line. Susan H. Mather, Michael S. Simberkoff, and Peter C. Jensen. June 1988, p. 35.

AIDS: Recognizing patients' emotional needs/Practitioner Forum. Ernesto Castro. March 1988, p. 19.

Detection of antibodies to human immunodeficiency virus: Principles, use, and interpretation/Current Topics in Clinical Virology. Brigitte P. Griffith, David Ferguson, and Marie L. Landry. September 1988, p. 49.

Gastrointestinal Kaposi's sarcoma in AIDS. N.S. Mann and S.A. Hyder. August 1988, p. 45.

Treating AIDS patients: Clinical, legal, and ethical issues. Thomas W. Miller and Anthony G. Belak. October 1988, p. 37.

AMBULATORY CARE

Ambulatory care pharmacy/Practitioner Forum. Robert L. Grimm. April 1988, p. 13.

Consequences of exclusion from VA outpatient care, The. Elly Budiman-Mak, William Stiers, and Frank Vozak. July 1988, p. 45.

Improving the structure of ambulatory care. David Webb. April 1988, p. 39.

Internal medicine on wheels: A six-year follow-up of the MediVAn. Sylvia K. Oboler and Thomas J. Meyer. October 1988, p. 99.

Patient visits: A survey of veterans with musculoskeletal disorders. W. Anthony Allison. February 1988, p. 72.

BYLINES FROM THE BOARD

Culpable institutions and angry survivors. Jacob D. Lindy. October 1988, p. 11.

Dentistry yesterday, today, and tomorrow. Abraham Kobren. August 1988, p. 11.

House Calls. Ludlow M. Pence. February 1988, p. 11

Integrating preventive medicine into the VA. Joan M. Altekruse. May 1988, p. 11.

Medical malpractice actions in the VA or, how to sue the government. Jeanne Anne Steffin. July 1988, p. 11.

NSAID gastropathy: Old problems, new answers. Sanford H. Roth. March 1988, p. 13.

Pain as a metaphor. Ernest W. Johnson. June 1988, p. 11.

Quality assurance in the hospital environment. G. Paul Sesin. April 1988, p. 11.

Still a burning issue. James F. Hammarsten. December 1988, p. 11.

Treating schizophrenia. Harold R. Dickman. January 1988, p. 10.

VA in wonderland, The. Robert M. Donati. September 1988, p. 11.

CAPITAL COMMENT

Addressing the future of long-term care: Part II. Jonathan Sunshine. January 1988, p. 65.

Conflict of interest: A wrap-up. Jonathan Sunshine. October 1988, p. 55.

Conflict of interest at the VA. Jonathan Sunshine. May 1988, p. 69.

Conflict of interest: How to get into trouble. Jonathan Sunshine. September 1988, p. 77.

Exclusive: The CMD discusses conflict of interest: An interview with John Gronvall, MD. Jonathan Sunshine. June 1988, p. 69.

Interview with Paul Errera, MD, An. Jonathan Sunshine. August 1988, p. 57.

New look for VA health care planning, A. Jonathan Sunshine. February 1988, p. 79.

Procreative services at the VA: A fertile topic. Jonathan Sunshine. November 1988, p. 59.

Running out of resources at the VA. Jonathan Sunshine. December 1988, p. 55.

Some thoughts in memoriam. Jonathan Sunshine. July 1988, p. 69.

Veterans' budget for veterans' health care, The. Jonathan Sunshine. March 1988, p. 87.

What the independent budget recommends. Jonathan Sunshine. April 1988, p. 69.

CLINICAL DRUG EVALUATION

Aztreonam. Loren Abad Niles. January 1988, p. 55.

Cefotetan. Jennifer Kong. April 1988, p. 109.

Cefuroxime axetil. Tracy Wong. November 1988, p. 89.

Fluoxetine. Patricia Lowe. October 1988, p. 81.

Human insulin. Julio R. Lopez. February 1988, p. 63.

Ipratropium bromide. William J. Falbe, March 1988, p. 71.

Lisinopril. Mahkameh Salehi. August 1988, p. 73.

Lovastatin. Kathi Servis. May 1988, p. 97.

Timentin®: A combination antibiotic. Cinda Christensen. June 1988, p. 93.

COOPERATIVE STUDIES

VA biomedical research: An interview with Richard J. Greene. August 1988, p. 51.



INDEX 1988 VA PRACTITIONER

SUBJECT INDEX

AIDS

AIDS and the VA: A report from the front line. Susan H. Mather, Michael S. Simberkoff, and Peter C. Jensen. June 1988, p. 35.

AIDS: Recognizing patients' emotional needs/Practitioner Forum. Ernesto Castro. March 1988, p. 19.

Detection of antibodies to human immunodeficiency virus: Principles, use, and interpretation/Current Topics in Clinical Virology. Brigitte P. Griffith, David Ferguson, and Marie L. Landry. September 1988, p. 49.

Gastrointestinal Kaposi's sarcoma in AIDS. N.S. Mann and S.A. Hyder. August 1988, p. 45.

Treating AIDS patients: Clinical, legal, and ethical issues. Thomas W. Miller and Anthony G. Belak. October 1988, p. 37.

AMBULATORY CARE

Ambulatory care pharmacy/Practitioner Forum. Robert L. Grimm. April 1988, p. 13.

Consequences of exclusion from VA outpatient care, The. Elly Budiman-Mak, William Stiers, and Frank Vozak. July 1988, p. 45.

Improving the structure of ambulatory care. David Webb. April 1988, p. 39.

Internal medicine on wheels: A six-year follow-up of the MediVAn. Sylvia K. Oboler and Thomas J. Meyer. October 1988, p. 99.

Patient visits: A survey of veterans with musculoskeletal disorders. W. Anthony Allison. February 1988, p. 72.

BYLINES FROM THE BOARD

Culpable institutions and angry survivors. Jacob D. Lindy. October 1988, p. 11.

Dentistry yesterday, today, and tomorrow. Abraham Kobren. August 1988, p. 11.

House Calls. Ludlow M. Pence. February 1988, p. 11

Integrating preventive medicine into the VA. Joan M. Altekruse. May 1988, p. 11.

Medical malpractice actions in the VA or, how to sue the government. Jeanne Anne Steffin. July 1988, p. 11.

NSAID gastropathy: Old problems, new answers. Sanford H. Roth. March 1988, p. 13.

Pain as a metaphor. Ernest W. Johnson. June 1988, p. 11.

Quality assurance in the hospital environment. G. Paul Sesin. April 1988, p. 11.

Still a burning issue. James F. Hammarsten. December 1988, p. 11.

Treating schizophrenia. Harold R. Dickman. January 1988, p. 10.

VA in wonderland, The. Robert M. Donati. September 1988, p. 11.

CAPITAL COMMENT

Addressing the future of long-term care: Part II. Jonathan Sunshine. January 1988, p. 65.

Conflict of interest: A wrap-up. Jonathan Sunshine. October 1988, p. 55.

Conflict of interest at the VA. Jonathan Sunshine. May 1988, p. 69.

Conflict of interest: How to get into trouble. Jonathan Sunshine. September 1988, p. 77.

Exclusive: The CMD discusses conflict of interest: An interview with John Gronvall, MD. Jonathan Sunshine. June 1988, p. 69.

Interview with Paul Errera, MD, An. Jonathan Sunshine. August 1988, p. 57.

New look for VA health care planning, A. Jonathan Sunshine. February 1988, p. 79.

Procreative services at the VA: A fertile topic. Jonathan Sunshine. November 1988, p. 59.

Running out of resources at the VA. Jonathan Sunshine. December 1988, p. 55.

Some thoughts in memoriam. Jonathan Sunshine. July 1988, p. 69.

Veterans' budget for veterans' health care, The. Jonathan Sunshine. March 1988, p. 87.

What the independent budget recommends. Jonathan Sunshine. April 1988, p. 69.

CLINICAL DRUG EVALUATION

Aztreonam. Loren Abad Niles. January 1988, p. 55.

Cefotetan. Jennifer Kong. April 1988, p. 109.

Cefuroxime axetil. Tracy Wong. November 1988, p. 89.

Fluoxetine. Patricia Lowe. October 1988, p. 81.

Human insulin. Julio R. Lopez. February 1988, p. 63.

Ipratropium bromide. William J. Falbe, March 1988, p. 71.

Lisinopril. Mahkameh Salehi. August 1988, p. 73.

Lovastatin. Kathi Servis. May 1988, p. 97.

Timentin®: A combination antibiotic. Cinda Christensen. June 1988, p. 93.

COOPERATIVE STUDIES

VA biomedical research: An interview with Richard J. Greene. August 1988, p. 51.

What's new and noteworthy in cooperative studies. Janet Gold. July 1988, p. 61.

CURRENT TOPICS IN CLINICAL VIROLOGY

Detection of antibodies to human immunodeficiency virus: Principles, use, and interpretation. Brigitte P. Griffith, David Ferguson, and Marie L. Landry. September 1988, p. 49.

Rapid viral diagnosis: The use of centrifugation cultures. Marie L. Landry. December 1988, p. 35.

DENTISTRY

Dentistry yesterday, today, and tomorrow/Bylines from the Board. Abraham Kobren. August 1988, p. 11.

More than meets the eye: The importance of dental-facial attractiveness. John Ofstehage. November 1988, p. 97.

Osseointegration and dental implants: The state of the art. Lauren L. Patton, Lawrence E. Scheitler, and Charles E. English. June 1988, p. 75.

Partners in dental research: The NIA/NIDR/VA project on oral health in aging. Robert R. Rhyne, Richard Adelson, Joan S. Wilentz, and Joanna Badinelli. February 1988, p. 41.

Preventive dental health care in the VA. Mark E. Davis. April 1988, p. 101.

EDUCATIONAL PROGRAMS

Advisory committee's impact on patient education, An. Ruth Hartmann, Ronald Santilli, Michael Franklin, Barbara Stevens, Ray Cary, and Mahendr Kochar. June 1988, p. 61.

Educating families of the mentally ill/Practitioner Forum. Jack Brown and Betty Barrett. March 1988, p. 19.

Improving the hospital discharge summary. Brian Flyer, Laurence Z. Rubenstein, Alan S. Robbins, G. Darryl Wieland, Daniel Henry, and Nada Cugalj. October 1988, p. 61.

Practical strategies for compliance. Joyce A. Cramer. February 1988, p. 109.

Training nurse-group therapists/Practitioner Forum. Bernadette D. Parker, Nancy Maehl, and Hilda Kanehl. October 1988, p. 15.

GENERAL MEDICINE

Beriberi in former POWs of the Japanese. William Paul Skelton. October 1988, p. 89.

Drug-resistant mycobacterium tuberculosis in a veteran population. Silverio M. Santiago, Adrian J. Williams, William B. Klaustermeyer, and Eleanor Nagai. January 1988, p. 87.

Movement and behavioral side effects of ethmozin. John C. Voris, Glenn N. Shaurette, and Fionan M. O'Griofa. March 1988, p. 95.

Phototherapy: Perspective from Brooklyn VAMC. Christine Sapka, Shakuntala Ratwani, and Yelva L. Lynfield. April 1988, p. 91.

GERIATRIC MEDICINE

Minority elderly in the VA. George Rajewski and James A. Haley. February 1988, p. 85.

On growing older and wiser: How to help the aging help themselves. Ruth A. Hartmann, Jean E. Bromley, and Edmund H. Duthie, Jr. November 1988, p. 69.

INTERVIEWS

Exclusive: The CMD discusses conflict of interest: An interview with John Gronvall, MD. Jonathan Sunshine. June 1988, p. 69.

Interview with Paul Errera, MD, An. Jonathan Sunshine. August 1988, p. 57.

VA biomedical research: An interview with Richard J. Greene. August 1988, p. 51.

MEDICAL MANAGEMENT

Concurrent review program for quality assurance, A/Practitioner Forum. Denise Marie Proctor. October 1988, p. 15.

Consequences of exclusion from VA outpatient care, The. Elly Budiman-Mak, William Stiers, and Frank Vozak. July 1988, p. 45.

Improving the hospital discharge summary. Brian Flyer, Laurence Z. Rubenstein, Alan S. Robbins, G. Darryl Wieland, Daniel Henry, and Nada Cugalj. October 1988, p. 61.

Managing and treating the blind veteran. Christopher J. Evans. May 1988, p. 41.

Practical strategies for compliance. Joyce A. Cramer. February 1988, p. 109.

Quality assurance in the triage area. Shirley Hines and Conrad C. Reisinger. January 1988, p. 76.

Spinal cord injury patients at non-SCI centers. Joseph D. Edwards, Jr. January 1988, p. 37.

Statistical tracking system for former POWs, A. Elizabeth Ahuja. September 1988, p. 65.

Treating the homeless veteran. Robert Rosenheck, Peggy Gallup, Catherine Leda, Robert Milstein, Philip Leaf, Irene M. Voynick, and Paul Errera. March 1988, p. 51.

Use of microcomputers for colonoscopy records, The. Ralph T. Guild, III, Donald J. Kastens, John R. Hood, and Jack D. Welsh. April 1988, p. 81.

VA health care for women: Filling in the blanks. Frances M. Weaver, Laurie A. Darcy, and Robin S. Turpin. November 1988, p. 43.

Waste management plan for VA facilities. Wayne L. Warren, J.I. Bregman, and Edward Findley. January 1988, p. 42

MEDICATION MANAGEMENT

Digibind: Digoxin-specific antibody fragments. Timothy R. Mickle, William J. Falbe, and Ronald L. Braden. February 1988, p. 93.

Dosing trends in glyburide and glipizide. Jennifer S.L. Kong, Julio Lopez, and Joseph S. Gee. December 1988, p. 64.

Medication refill clinic: A cost-effective alternative. Norman T. Suzuki and William B. Breuninger. April 1988, p. 57.

Methadone maintenance treatment. Paul Cushman, Jr. January 1988, p. 93.

Treating the assaultive patient with propranolol. Robert M.

INDEX

Greendyke, Daniel B. Schuster, Donald R. Kanter, and Sherry Verstreate. March 1988, p. 113.

MENTAL HEALTH CARE

Interview with Paul Errera, MD, An. Jonathan Sunshine. August 1988, p. 57.

From Yale professor to Washington bureaucrat: Policy and medicine. Paul Errera. May 1988, p. 81.

Mental health services for Vietnam veterans/Practitioner Forum. Michael E. Reaves, Roland M. Atkinson, Lial L. Kofoed, Michael J. Maxwell, and Cathy Ponzoha. June 1988, p. 15.

Methadone maintenance treatment. Paul Cushman, Jr. January 1988, p. 93.

Putting back the pieces: A unique rehabilitative approach for brain-injured patients. Jerome I. Boyar. December 1988, p. 47.

Sociometric survey of mental health patients at a VAMC/ Practitioner Forum. Eugene G. Peniston and R.S. Garrett. May 1988, p. 15.

Trends in VA mental health services for Vietnam veterans. Michael E. Reaves, Roland M. Atkinson, Catherine A. Ponzoha, and Lial L. Kofoed. July 1988, p. 93.

NEUROLOGY

Movement and behavioral side effects of ethmozin. John C. Voris, Glenn N. Shaurette, and Fionan M. O'Griofa. March 1988, p. 95.

Quantitative neuropsychiatry: The Brentwood movement disorders laboratory. Jeffrey L. Cummings and William Wirshing. February 1988, p. 99.

Spinal cord injury patients at non-SCI centers. Joseph D. Edwards, Jr. January 1988, p. 37.

Treating the assaultive patient with propranolol. Robert M. Greendyke, Daniel B. Schuster, Donald R. Kanter, and Sherry Verstreate. March 1988, p. 113.

OBITUARIES

From physician to patient: David M. Worthen, MD. David M. Worthen. July 1988, p. 73.

Some thoughts in memoriam. Jonathan Sunshine. July 1988, p. 69.

VA official dies: Francis E. Conrad, MD/Practitioner Forum. May 1988, p. 15.

PHARMACOLOGY

Ambulatory care pharmacy/Practitioner Forum. Robert L. Grimm. April 1988, p. 13.

Effective pharmacotherapy for post-traumatic stress disorder. Charles K. Embry and Bertha Callahan. May 1988, p. 57.

From Waco to VACO: Staying on top of pharmacy staffing. Betty Commander McGowan and Robert Ratliff. August 1988, p. 65.

Methods in pharmacy service quality assurance/Practitioner Forum. Robert L. Grimm. July 1988, p. 89.

PRACTITIONER FORUM

Absenteeism: Who, what, why. Costellia H. Talley and Henry C. Talley. September 1988, p. 15.

AIDS: Recognizing patients' emotional needs. Ernesto Castro. March 1988, p. 19.

Ambulatory care pharmacy. Robert L. Grimm. April 1988, p. 13.

A card is the key in blood pressure screening. Mary H. Smith, Mary Alice Yoham, Dorothy C. Payne, and Jacquelyn Radi. December 1988, p. 17.

Concurrent review program for quality assurance, A. Denise Marie Proctor. October 1988, p. 15.

Domiciliaries: A transitional bridge to community care. James McLean, James Bjornvick, Chester Wisley, William Fowler, Jo Tirone, and Joe German. January 1988, p. 14.

Educating families of the mentally ill. Jack Brown and Betty Barrett. March 1988, p. 19.

Home care versus intensive care for a ventilator-dependent veteran. Norma Boone Goldberg, Victor Stiebel, Jose Vasquez, Sirajuddin S. Khaja. February 1988, p. 15.

Mental health services for Vietnam veterans. Michael E. Reaves, Roland M. Atkinson, Lial L. Kofoed, Michael J. Maxwell, and Cathy Ponzoha. June 1988, p. 15.

Methods in pharmacy service quality assurance. Robert L. Grimm. July 1988, p. 89.

Organizational innovation: A support group for amputees. Jerrie Larson. November 1988, p. 15.

Protime clinic—meeting the client's needs, The. Cheryl Bacon Moore. January 1988, p. 15.

Psychiatric clinical nurse specialist. Sharon Almquist Job, Lynn Rae Sengbush, and Suzanne Mills Smith. April 1988, p. 13.

Reaching out to the homeless veteran. Melanie Duckworth and Debbie Waid. February 1988, p. 20.

Seventh Annual National Veterans Wheelchair Games. Kim Byers. February 1988, p. 15.

Smoking cessation clinic for psychiatric patients, A. David Schlenoff and Elizabeth Schlenoff. May 1988, p. 77.

Sociometric survey of mental patients at a VAMC. Eugene G. Peniston and R.S. Garrett. May 1988, p. 15.

Spouse support group helps brain damaged to cope. Herbert Goldman, Kenneth M. Kleinman, and D.J. Hubbard. July 1988, p. 89.

Stress recovery treatment. Dharm S. Bains, Jim Frazee, Donald Amidon, Gordon K. Hare, and Patrick K. Munley. July 1988, p. 90.

Training nurse-group therapists. Bernadette D. Parker, Nancy Maehl, and Hilda Kanehl. October 1988, p. 15.

VA as a drug-free workplace, The. Everett Chasen. August 1988, p. 23.

VA official dies: Francis E. Conrad, MD. May 1988, p. 15.

PROFILES

American Lake VAMC. Tacoma, Washington. October 1988, p. 24.

Ann Arbor VAMC. Ann Arbor, Michigan. August 1988, p. 30.

Brockton & West Roxbury VAMC. Massachusetts. February 1988, p. 26.

Fargo VAM&ROC. Fargo, North Dakota. July 1988, p. 32.

Martinez VAMC. Martinez, California. January 1988, p. 22.

Martinsburg VAMC. Martinsburg, West Virginia. September 1988, p. 26.

Nashville VAMC. Nashville, Tennessee. April 1988, p. 24.

Providence VAMC. Providence, Rhode Island. November 1988, p. 22.

continued

The Antiemetic Prescribed Most*

Compazine®

brand of

prochlorperazine

See complete prescribing information in SK&F literature or *PDR*. The following is a brief summary.

Indications: For control of severe nausea and vomiting.

Contraindications: Comatose or greatly depressed states due to C.N.S. depressants; pediatric surgery; use in children under 2 years of age or under 20 lbs.; use in children for conditions for which dosage has not been established.

Warnings: The extrapyramidal symptoms which can occur secondary to 'Compazine' may be confused with the central nervous system signs of an undiagnosed primary disease responsible for the vomiting, e.g., Reye's syndrome or other encephalopathy. The use of 'Compazine' and other potential hepatotoxins should be avoided in children and adolescents whose signs and symptoms suggest Reye's syndrome.

May cause tardive dyskinesia in some patients on neuroleptic (antipsychotic) therapy, usually long-term. This syndrome consists of potentially irreversible, involuntary dyskinetic movements. The risk of tardive dyskinesia and likelihood of irreversibility are thought related to duration of treatment and total cumulative dose of neuroleptic drugs.

Neuroleptic Malignant Syndrome (NMS), a potentially fatal symptom complex, has been reported in association with antipsychotic drugs. Clinical manifestations include: hyperpyrexia, muscle rigidity, altered mental status and evidence of autonomic instability.

The management of NMS should include 1) immediate discontinuation of antipsychotic drugs and other drugs not essential to concurrent therapy, 2) intensive symptomatic treatment and medical monitoring, and 3) treatment, if available, of any concomitant serious medical problems.

'Compazine' Ampuls contain sodium bisulfite and sodium sulfite, sulfites that may cause allergic-type reactions including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in certain susceptible people. The overall prevalence of sulfite sensitivity in the general population is unknown and probably low. Sulfite sensitivity is seen more frequently in asthmatic than in nonasthmatic people.

Use in patients with bone marrow depression only when potential benefits outweigh risks. Patients who develop a hypersensitivity reaction (e.g., blood dyscrasias or jaundice) to a phenothiazine generally should not be reexposed to any phenothiazine. Caution patients about activities requiring alertness (e.g., operating vehicle or machinery), especially during the first few days' therapy. Prochlorperazine may intensify or prolong the action of other C.N.S. depressants.

Use in pregnancy is not recommended except in cases so serious and intractable that, in the physician's judgment, drug intervention is required and potential benefits outweigh possible hazards. There have been instances of prolonged jaundice, extrapyramidal signs, hyperreflexia or hyporeflexia in newborn infants whose mothers received phenothiazines. There is evidence that phenothiazines are excreted in the breast milk of nursing mothers.

Precautions: The antiemetic action of 'Compazine' may mask the signs and symptoms of overdosage of other drugs and may obscure the diagnosis and treatment of other conditions such as intestinal obstruction, brain tumor and Reye's syndrome (see Warnings). Postoperative aspiration of vomitus has occurred in a few surgical patients who received prochlorperazine as an antiemetic. When used concomitantly with cancer chemotherapeutic drugs, may obscure vomiting as a sign of these agents' toxicity. Deep sleep and coma have been reported with prochlorperazine, usually with overdosage.

Neuroleptic drugs cause elevated prolactin levels that persist during chronic administration. Since approximately one-third of human breast cancers are prolactin-dependent *in vitro*, this elevation is of potential importance if neuroleptic drug administration is contemplated in a patient with a previously detected breast cancer. Neither clinical nor epidemiologic studies to date, however, have shown an association between the chronic administration of neuroleptic drugs and mammary tumorigenesis. Chromosomal aberrations in spermatocytes and abnormal sperm have been demonstrated in rodents treated with certain neuroleptics.

Permanently stop neuroleptic therapy if neuromuscular reactions occur in pregnant women or in children.

In children with acute illnesses or dehydration, use only under close supervision. Avoid high doses and parenteral administration when cardiovascular system is impaired since hypotension has occurred. Use cautiously in patients with glaucoma. Use with caution in persons who will be exposed to extreme heat since phenothiazines may interfere with thermoregulatory mechanisms. Phenothiazines can diminish the effect of oral anticoagulants. Phenothiazines can produce alpha-adrenergic blockade. Thiazide diuretics may accentuate orthostatic hypotension that may occur with phenothiazines. Antihypertensive effects of guanethidine and related compounds may be counteracted when phenothiazines are used concomitantly. Concomitant administration of phenothiazines with propranolol results in increased plasma levels of both drugs and may also precipitate phenytoin toxicity. Phenothiazines may lower the convulsive threshold; dosage adjustments of anticonvulsants may be necessary. Presence of phenothiazines may produce false positive phenylketonuria (PKU) test results. Patients should not receive 'Compazine' 48 hours before or 24 hours after myelography with the contrast medium metrizamide.

Adverse Reactions: Drowsiness, dizziness, amenorrhea, blurred vision, skin reactions. Hypotension. Cholestatic jaundice, leukopenia, agranulocytosis. Fatty changes in the liver have been observed in a few patients who died while receiving the drug (no causal relationship has been established). Neuromuscular (extrapyramidal) reactions: motor restlessness, dystonias, pseudo-parkinsonism, tardive dyskinesia, and a variant, tardive dystonia. Contact dermatitis is a possibility if 'Compazine' Injection (solution) inadvertently gets on hands or clothing.

Other adverse reactions reported with 'Compazine' or other phenothiazines: Some adverse effects are more frequent or intense in specific disorders (e.g., severe hypotension in mitral insufficiency or pheochromocytoma): Grand mal and petit mal convulsions; altered cerebrospinal fluid proteins; cerebral edema; prolongation and intensification of the action of C.N.S. depressants, atropine, heat and organophosphorus insecticides; dryness of mouth, nasal congestion, headache, nausea, constipation, obstipation, adynamic ileus, ejaculatory disorders/impotence, priapism, atonic colon, urinary retention, miosis and mydriasis; reactivation of psychotic processes, catatonic-like states; hypotension (sometimes fatal); cardiac arrest; pancytopenia, thrombocytopenic purpura, eosinophilia, hemolytic anemia, aplastic anemia; biliary stasis; hyperglycemia, hypoglycemia, glycosuria, lactation, galactorrhea, gynecomastia, menstrual irregularities, false positive pregnancy tests; photosensitivity, itching, erythema, urticaria, eczema up to exfoliative dermatitis; asthma, laryngeal edema; angioneurotic edema, anaphylactoid reactions; peripheral edema; reversed epinephrine effect; hyperpyrexia; mild fever after large I.M. doses; increased appetite; increased weight; a systemic lupus erythematosus-like syndrome; pigmentary retinopathy; with prolonged administration of substantial doses, skin pigmentation, epithelial keratopathy, and lenticular and corneal deposits.

EKG changes have been reported. Discontinue long-term, high-dose therapy gradually.

Note: Sudden death in patients taking phenothiazines (apparently due to cardiac arrest or asphyxia due to failure of cough reflex) has been reported.

Supplied: Tablets—5, 10 and 25 mg., in bottles of 100; Spansule® capsules—10, 15 and 30 mg., in bottles of 50; Injection—5 mg./mL. in 2 mL. ampuls, 10 mL. vials and 2 mL. disposable syringes; Suppositories—2½, 5 and 25 mg.; Syrup—5 mg./5 mL.; Single Unit Packages of 100 (intended for institutional use only)—5 and 10 mg. tablets; 10, 15 and 30 mg. 'Spansule' capsules.

© SmithKline Beckman Corporation, 1988

BRS-CZ L74

*Data on file, SK&F

Smith Kline & French Laboratories
A SMITHKLINE BECKMAN COMPANY
Philadelphia, PA 19101

SK&F

INDEX

San Juan VAMC. San Juan, Puerto Rico. March 1988, p. 26.
Shreveport VAMC. Shreveport, Louisiana. June 1988, p. 22.
West Haven VAMC. West Haven, Connecticut. May 1988, p. 28.
Wichita VAMC. Wichita, Kansas. December 1988, p. 22.

PSYCHIATRY

Cycle of schizophrenia: A sociocultural view, The. Javier I. Escobar, Eugenia T. Randolph, Denise Paz, and Mary Ann Hill. November 1988, p. 81.
Educating families of the mentally ill/Practitioner Forum. Jack Brown and Betty Barrett. March 1988, p. 19.
Gender differences in veteran psychiatric inpatients. Edith Pepper and John Fryer. March 1988, p. 77.
Getting back to business: Vocational readjustment for psychiatric inpatients. James E. Pendorf. September 1988, p. 87.
Mental health services for Vietnam veterans/Practitioner Forum. Michael E. Reaves, Roland M. Atkinson, Lial L. Kofoed, Michael J. Maxwell, and Cathy Ponzoha. June 1988, p. 15.
Psychiatric clinical nurse specialist/Practitioner Forum. Sharon Almquist Job, Lynn Rae Sengbush, and Suzanne Mills Smith. April 1988, p. 13.
Quantitative neuropsychiatry: The Brentwood movement disorders laboratory. Jeffrey L. Cummings and William Wirshing. February 1988, p. 99.
Smoking cessation clinic for psychiatric patients, A/Practitioner Forum. David Schlenoff and Elizabeth Schlenoff. May 1988, p. 77.
Sociometric survey of mental patients at a VAMC/Practitioner Forum. Eugene G. Peniston and R.S. Garrett. May 1988, p. 15.
Treating schizophrenia/Bylines from the Board. Harold R. Dickman. January 1988, p. 10.
Trends in VA mental health services for Vietnam veterans. Michael E. Reaves, Roland M. Atkinson, Catherine A. Ponzoha, and Lial L. Kofoed. July 1988, p. 93.
VA psychiatric malpractice claims. Charles E. Beck. April 1988, p. 45.

PTSD (POST-TRAUMATIC STRESS DISORDER)

Effective pharmacotherapy for post-traumatic stress disorder. Charles K. Embry and Bertha Callahan. May 1988, p. 57.
Importance of military history in identifying PTSD, The. Mary Koczur Kenny, Anne Flickinger, and Mary Ann Talka. March 1988, p. 101.
Stages of treatment in PTSD. Stephen T. Perconte. February 1988, p. 47.
Stress recovery treatment/Practitioner Forum. Dharm S. Baines, Jim Frazee, Donald Amidon, Gordon K. Hare, and Patrick K. Munley. July 1988, p. 90.

REHABILITATION MEDICINE

Domiciliaries: A transitional bridge to community care/Practitioner Forum. James McLean, James Bjornvick, Chester Wisley, William Fowler, Jo Tirone, and Joe German. January 1988, p. 14.
Getting back to business: Vocational readjustment for psychiatric inpatients. James E. Pendorf. September 1988, p. 87.

Methadone maintenance treatment. Paul Cushman, Jr. January 1988, p. 93.
Putting back the pieces: A unique rehabilitative approach for brain-injured patients. Jerome I. Boyar. December 1988, p. 47.
Spouse support group helps brain damaged to cope/Practitioner Forum. Herbert Goldman, Kenneth M. Kleinman, and D.J. Hubbard. July 1988, p. 89.

RESEARCH
VA biomedical research: An interview with Richard J. Greene. August 1988, p. 51.

SMOKING
Attitudes of VA employees toward smoking and smoking policy. T. Schenkenberg, W.L. Hodson, and Scott Hill. March 1988, p. 39.
Best and the worst of the smoking cessation programs, The. James E. Bailey. November 1988, p. 49.
Smoking cessation clinic for psychiatric patients, A/Practitioner Forum. David Schlenoff and Elizabeth Schlenoff. May 1988, p. 77.

SPEAKING OUT
Changing the way physicians get paid. Harry Schwartz. August 1988, p. 27.
Drawing the line on "special" procedures. Harry Schwartz. January 1988, p. 19.
Election '88: The future in retrospect. Harry Schwartz. November 1988, p. 17.
Health benefits and the puzzle of privilege. Harry Schwartz. May 1988, p. 19.
Losing sight of the silver lining. Harry Schwartz. June 1988, p. 19.
Making and unmaking decisions. Harry Schwartz. July 1988, p. 27.
No monopoly on mistakes: The other side of the coin. Harry Schwartz. April 1988, p. 19.
Ring out the old plan, bring in the new? Harry Schwartz. October 1988, p. 19.
Taking a knife to surgeons' fees. Harry Schwartz. September 1988, p. 21.
Troubled system is not an inadequate system, A. Harry Schwartz. December 1988, p. 19.
VA cabinet department: Good news or bad?, The. Harry Schwartz. February 1988, p. 21.
VA cabinet post: Thoughts from friends and foes, The. Harry Schwartz. March 1988, p. 23.

SPINAL CORD INJURY
Spinal cord injury patients at non-SCI centers. Joseph D. Edwards, Jr. January 1988, p. 37.

SURGERY
Perioperative use of beta-adrenergic blockers. Frank K. Kan. July 1988, p. 79.
Successful hernia clinic for veterans, A. Maximo Deysine and Harry S. Soroff. September 1988, p. 41.
Use of microcomputers for colonoscopy records, The. Ralph T. Guild III, Donald J. Kastens, John R. Hood, and Jack D. Welsh. April 1988, p. 81.

VA EVENTS
Middleton Award 1988: Gerald Reaven, MD. March 1988, p. 47.
Wheelchair athletes meet the challenge. Roxanne Fischetti, September 1988, p. 72.

AUTHOR INDEX

A
Adelson, R. See Rhyne, RR. February 1988.
Ahuja, E. A statistical tracking system for former POWs. September 1988, p. 65.
Allison, WA. Patient visits: A survey of veterans with musculoskeletal disorders. February 1988, p. 72.
Altekruse, JM. Bylines from the Board/Integrating preventive medicine into the VA. May 1988, p. 11.
Amidon, D. See Bains, DS. July 1988.
Atkinson, RM. See Reaves, ME. June 1988.
Atkinson, RM. See Reaves, ME. July 1988.

B
Badinelli, J. See Rhyne, RR. February 1988.
Bailey, JE. The best and the worst of the smoking cessation programs. November 1988, p. 49.
Bains, DS; Frazee, J; Amidon, D; Hare, GK; Munley, PK. Practitioner Forum/Stress recovery treatment. July 1988, p. 90.
Barrett, B. See Brown, J. March 1988.
Beck, CE. VA psychiatric malpractice claims. April 1988, p. 45.
Belak, AG. See Miller, TW. October 1988.
Bjornvick, J. See McLean, J. January 1988.
Boyar, J. Putting back the pieces: A unique rehabilitative approach for brain-injured patients. December 1988, p. 47.
Braden, RL. See Mickle, TR. February 1988.
Bregman, JI. See Warren, WL. January 1988.
Breuninger, WB. See Suzuki, NT. April 1988.
Bromley, JE. See Hartmann, RA. November 1988.
Brown, J; Barrett, B. Practitioner Forum/Educating families of the mentally ill. March 1988, p. 19.
Budiman-Mak, E; Stiers, W; Vozak, F. The consequences of exclusion from VA outpatient care. July 1988, p. 45.
Byers, K. Practitioner Forum/Seventh Annual National Veterans Wheelchair Games. February 1988, p. 15.

C
Callahan, B. See Embry, CK. May 1988.
Cary, R. See Hartmann, R. June 1988.
Castro, E. Practitioner Forum/AIDS: Recognizing patients' emotional needs. March 1988, p. 19.
Chasen, E. Practitioner Forum/The VA as a drug-free workplace. August 1988, p. 23.
Christensen, C. Clinical Drug Evaluation/Timentin®: A combination antibiotic. June 1988, p. 93.

continued

INDEX

Cramer, JA. Practical strategies for compliance. February 1988, p. 109.
Cugalj, N. See Flyer, B. October 1988.
Cummings, JL; Wirshing, W. Quantitative neuropsychiatry: The Brentwood movement disorders laboratory. February 1988, p. 99.
Cushman, P, Jr. Methadone maintenance treatment. January 1988, p. 93.

D
Darcy, LA. See Weaver, FM. November 1988.
Davis, ME. Preventive dental health care in the VA. April 1988, p. 101.
Deysine, M; Soroff, HS. A successful hernia clinic for veterans. September 1988, p. 41.
Dickman, HR. Bylines from the Board/Treating schizophrenia. January 1988, p. 10.
Donati, RM. Bylines from the Board/The VA in wonderland. September 1988, p. 11.
Duckworth, M; Waid, D. Practitioner Forum/Reaching out to the homeless veteran. February 1988, p. 20.
Duthie, EH. See Hartmann, RA. November 1988.

E
Edwards, JD, Jr. Spinal cord injury patients at non-SCI centers. January 1988, p. 37.
Embry, CK; Callahan, B. Effective pharmacotherapy for posttraumatic stress disorder. May 1988, p. 57.
English, CE. See Patton, LL. June 1988.
Errera, P. From Yale professor to Washington bureaucrat: Policy and medicine. May 1988, p. 81.
Errera, P. See Rosenheck, R. March 1988.
Escobar, JI; Randolph, ET; Paz, D; Hill, MA. The cycle of schizophrenia: A sociocultural view. November 1988, p. 81.
Evans, CJ. Managing and treating the blind veteran. May 1988, p. 41.

F
Falbe, WJ. Clinical Drug Evaluation/Ipratropium bromide. March 1988, p. 71.
Falbe, WJ. See Mickle, TR. February 1988.
Ferguson, D. See Griffith, BP. September 1988.
Findley, E. See Warren, WL. January 1988.
Fischetti, R. Wheelchair athletes meet the challenge. September 1988, p. 72.
Flickinger, A. See Kenny, MK. March 1988.
Flyer, B; Rubenstein, LZ; Robbins, AS; Wieland, GD; Henry, D; Cugalj, N. Improving the hospital discharge summary. October 1988, p. 61.
Fowler, W. See McLean, J. January 1988.
Franklin, M. See Hartmann, R. June 1988.
Frazee, J. See Bains, DS. July 1988.
Fryer, J. See Pepper, E. March 1988.

G
Gallup, P. See Rosenheck, R. March 1988.
Garrett, RS. See Peniston, EG. May 1988.
Gee, JS. See Kong, JSL. December 1988.
German, J. See McLean, J. January 1988.
Gold, J. What's new and noteworthy in cooperative studies. July 1988, p. 61.
Goldberg, NB; Stiebel, V; Vasquez, J; Khaja, SS. Practitioner Forum/Home care versus intensive care for a ventilator-dependent veteran. February 1988, p. 15.
Goldman, H; Kleinman, KM; Hubbard, DJ. Practitioner Forum/Spouse support group helps brain damaged to cope. July 1988, p. 89.
Greendyke, RM; Schuster, DB; Kanter, DR; Verstreate, S. Treating the assaultive patient with propranolol. March 1988, p. 113.
Griffith, BP; Ferguson, D; Landry, ML. Current Topics in Clinical Virology/Detection of antibodies to human immunodeficiency virus: Principles, use, and interpretation. September 1988, p. 49.
Grimm, RL. Practitioner Forum/Ambulatory care pharmacy. April 1988, p. 13.
Grimm, RL. Practitioner Forum/Methods in pharmacy service quality assurance. July 1988, p. 89.
Guild, RT; Kastens, DJ; Hood, JR; Welsh, JD. The use of microcomputers for colonoscopy records. April 1988, p. 81.

H
Haley, JA. See Rajewski, G. February 1988.
Hare, GK. See Bains, DS. July 1988.
Hartmann, RA; Bromley, JE; Duthie, EH, Jr. On growing older and wiser: How to help the aging help themselves. November 1988, p. 69.
Hartmann, R; Santilli, R; Franklin, M; Stevens, B; Cary, R; Kochar, M. An advisory committee's impact on patient education. June 1988, p. 61.
Henry, D. See Flyer, B. October 1988.
Hill, MA. See Escobar, JI. November 1988.
Hill, S. See Schenkenberg, T. March 1988.
Hines, S; Reisinger, CC. Quality assurance in the triage area. January 1988, p. 76.
Hodson, WL. See Schenkenberg, T. March 1988.
Hood, JR. See Guild, RT. April 1988.
Hubbard, DJ. See Goldman, H. July 1988.
Hyder, SA. See Mann, NS. August 1988.

J
Jensen, PC. See Mather, SH. June 1988.
Job, SA; Sengbush, LR; Smith, SM. Practitioner Forum/Psychiatric clinical nurse specialist. April 1988, p. 13.
Johnson, EW. Bylines from the Board/Pain as a metaphor. June 1988, p. 11.

K
Kan, FK. Perioperative use of beta-adrenergic blockers. July 1988, p. 79.
Kanehl, H. See Parker, BD. October 1988.
Kanter, DB. See Greendyke, RM. March 1988.
Kastens, DJ. See Guild, RT. April 1988.
Kenny, MK; Flickinger, A; Talka, MA. The importance of military history in identifying PTSD. March 1988, p. 101.
Khaja, SS. See Goldberg, NB. February 1988.
Klaustermeyer, WB. See Santiago, SM. January 1988.
Kleinman, KM. See Goldman, H. July 1988.
Kobren, A. Bylines from the Board/Dentistry yesterday, today, and tomorrow. August 1988, p. 11.

Kochar, M. See Hartmann, R. June 1988.
Kofoed, LL. See Reaves, ME. June 1988.
Kofoed, LL. See Reaves, ME. July 1988.
Kong, J. Clinical Drug Evaluation/Cefotetan. April 1988, p. 109.
Kong, JSL; Lopez, J; Gee, JS. Dosing trends in glyburide and glipizide. December 1988, p. 64.

L
Landry, ML. Current Topics in Clinical Virology/Rapid viral diagnosis: The use of centrifugation cultures. December 1988, p. 35.
Landry, ML. See Griffith, BP. September 1988.
Larson, J. Practitioner Forum/Organizational innovation: A support group for amputees. November 1988, p. 15.
Leaf, P. See Rosenheck, R. March 1988.
Leda, C. See Rosenheck, R. March 1988.
Lindy, JD. Bylines from the Board/Culpable institutions and angry survivors. October 1988, p. 11.
Lopez, J. See Kong, JSL. December 1988.
Lopez, JR. Clinical Drug Evaluation/Human insulin. February 1988, p. 63.
Lowe, P. Clinical Drug Evaluation/Fluoxetine. October 1988, p. 81.
Lynfield, YL. See Sapka, C. April 1988.

M
Maehl, N. See Parker, BD. October 1988.
Mann, NS; Hyder, SA. Gastrointestinal Kaposi's sarcoma in AIDS. August 1988, p. 45.
Mather, SH; Simkerkoff, MS; Jensen, PC. AIDS and the VA: A report from the front line. June 1988, p. 35.
Maxwell, MJ. See Reaves, ME. June 1988.
McGowan, BC; Ratliff, R. From Waco to VACO: Staying on top of pharmacy staffing. August 1988, p. 65.
McLean, J; Bjornvick, J; Wisley, C; Fowler, W; Tirone, J; German, J. Practitioner Forum/Domiciliaries: A transitional bridge to community care. January 1988, p. 14.
Meyer, TJ. See Oboler, SK. October 1988.
Mickle, TR; Falbe, WJ; Braden, RL. Digibind: Digoxin-specific antibody fragments. February 1988, p. 93.
Miller, TW; Belak, AG. Treating AIDS patients: Clinical, legal, and ethical issues. October 1988, p. 37.
Milstein, R. See Rosenheck, R. March 1988.
Moore, CB. Practitioner Forum/The protime clinic—meeting the client's needs. January 1988, p. 15.
Munley, PK. See Bains, DS. July 1988.

N
Nagai, E. See Santiago, SM. January 1988.
Niles, LA. Clinical Drug Evaluation/Aztreonam. January 1988, p. 55.

O
O'Griofa, FM. See Voris, JC. March 1988.
Oboler, SK; Meyer, TJ. Internal medicine on wheels: A six-year follow-up of the MediVAn. October 1988, p. 99.
Ofstehage, J. More than meets the eye: The importance of dental-facial attractiveness. November 1988, p. 97.

P
Parker, BD; Maehl, N; Kanehl, H. Practitioner Forum/Training nurse-group therapists. October 1988, p. 15.
Patton, LL; Scheitler, LE; English, CE. Osseointegration and dental implants: The state of the art. June 1988, p. 75.
Paz, D. See Escobar, JI. November 1988.
Pence, LM. Bylines from the Board/House Calls. February 1988, p. 11.
Pendorf, JE. Getting back to business: Vocational readjustment for psychiatric inpatients. September 1988, p. 87.
Peniston, EG; Garrett, RS. Practitioner Forum/Sociometric survey of mental patients at a VAMC. May 1988, p. 15.
Pepper, E; Fryer, J. Gender differences in veteran psychiatric patients. March 1988, p. 77.
Perconte, ST. Stages of treatment in PTSD. February 1988, p. 47.
Ponzoha, C. See Reaves, ME. June 1988.
Ponzoha, C. See Reaves, ME. July 1988.
Proctor, DM. Practitioner Forum/A concurrent review program for quality assurance. October 1988, p. 15.

R
Rajewski, G; Haley, JA. Minority elderly in the VA. February 1988, p. 85.
Randolph, ET. See Escobar, JI. November 1988.
Ratliff, R. See McGowan, BC. August 1988.
Ratwani, S. See Sapka, C. April 1988.
Reaves, ME; Atkinson, R; Kofoed, LL; Maxwell, MJ; Ponzoha, C. Practitioner Forum/Mental health services for Vietnam veterans. June 1988, p. 15.
Reaves, ME; Atkinson, R; Ponzoha, C; Kofoed, LL. Trends in VA mental health services for Vietnam veterans. July 1988, p. 93.
Reisinger, CC. See Hines, H. January 1988.
Rhyne, RR; Adelson, R; Wilentz, JS; Badinelli, J. Partners in dental research: The NIA/NIDR/VA project on oral health in aging. February 1988, p. 41.
Robbins, AS. See Flyer, B. October 1988.
Rosenheck, R; Gallup, P; Leda, C; Milstein, R; Leaf, P; Voynick, IM; Errera, P. Treating the homeless veteran. March 1988, p. 51.
Roth, SH. Bylines from the Board/NSAID gastropathy: Old problems, new answers. March 1988, p. 13.
Rubenstein, LZ. See Flyer, B. October 1988.

S
Salehi, M. Clinical Drug Evaluation/Lisinopril. August 1988, p. 73.
Santiago, SM; Williams, AD; Klaustermeyer, WB; Nagai, E. Drug-resistant mycobacterium tuberculosis in a veteran population. January 1988, p. 87.
Santilli, R. See Hartmann, R. June 1988.
Sapka, C; Ratwani, S; Lynfield, YL. Phototherapy: Perspective from Brooklyn VAMC. April 1988, p. 91.
Scheitler, LE. See Patton, LL. June 1988.
Schenkenberg, T; Hodson, WL; Hill, S. Attitudes of VA employees toward smoking and smoking policy. March 1988, p. 39.
Schlenoff, D; Schlenoff, E. Practitioner Forum/A smoking cessation clinic for psychiatric patients. May 1988, p. 77.

continued

Reference: 1. Sontag S, Robinson M, McCallum R, et al: Ranitidine therapy for gastroesophageal reflux disease. Results of a large double-blind trial. *Arch Intern Med* 1987;147:1485-1491.

ZANTAC® 150 Tablets (ranitidine hydrochloride) **ZANTAC® 300 Tablets (ranitidine hydrochloride)** **BRIEF SUMMARY**

The following is a brief summary only. Before prescribing, see complete prescribing information in ZANTAC® product labeling.

INDICATIONS AND USAGE: ZANTAC® is indicated in:

1. Short-term treatment of **active duodenal ulcer.** Most patients heal within four weeks.
2. **Maintenance therapy** for duodenal ulcer patients at reduced dosage after healing of acute ulcers.
3. The treatment of **pathological hypersecretory conditions** (eg, Zollinger-Ellison syndrome and systemic mastocytosis).
4. Short-term treatment of **active, benign gastric ulcer.** Most patients heal within six weeks and the usefulness of further treatment has not been demonstrated.
5. Treatment of **gastroesophageal reflux disease (GERD).** Symptomatic relief commonly occurs within one or two weeks after starting therapy. Therapy for longer than six weeks has not been studied.

In active duodenal ulcer; active, benign gastric ulcer; hypersecretory states; and GERD, concomitant antacids should be given as needed for relief of pain.

CONTRAINDICATIONS: ZANTAC® is contraindicated for patients known to have hypersensitivity to the drug.

PRECAUTIONS: General: 1. Symptomatic response to ZANTAC® therapy does not preclude the presence of gastric malignancy.

2. Since ZANTAC is excreted primarily by the kidney, dosage should be adjusted in patients with impaired renal function (see DOSAGE AND ADMINISTRATION). Caution should be observed in patients with hepatic dysfunction since ZANTAC is metabolized in the liver.

Laboratory Tests: False-positive tests for urine protein with Multistix® may occur during ZANTAC therapy, and therefore testing with sulfosalicylic acid is recommended.

Drug Interactions: Although ZANTAC has been reported to bind weakly to cytochrome P-450 in vitro, recommended doses of the drug do not inhibit the action of the cytochrome P-450-linked oxygenase enzymes in the liver. However, there have been isolated reports of drug interactions that suggest that ZANTAC may affect the bioavailability of certain drugs by some mechanism as yet unidentified (eg, a pH-dependent effect on absorption or a change in volume of distribution).

Carcinogenesis, Mutagenesis, Impairment of Fertility: There was no indication of tumorigenic or carcinogenic effects in lifespan studies in mice and rats at doses up to 2,000 mg/kg/day.

Ranitidine was not mutagenic in standard bacterial tests (*Salmonella, Escherichia coli*) for mutagenicity at concentrations up to the maximum recommended for these assays.

In a dominant lethal assay, a single oral dose of 1,000 mg/kg to male rats was without effect on the outcome of two matings per week for the next nine weeks.

Pregnancy: *Teratogenic Effects: Pregnancy Category B:* Reproduction studies have been performed in rats and rabbits at doses up to 160 times the human dose and have revealed no evidence of impaired fertility or harm to the fetus due to ZANTAC. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.

Nursing Mothers: ZANTAC is secreted in human milk. Caution should be exercised when ZANTAC is administered to a nursing mother.

Pediatric Use: Safety and effectiveness in children have not been established.

Use in Elderly Patients: Ulcer healing rates in elderly patients (65 to 82 years of age) were no different from those in younger age groups. The incidence rates for adverse events and laboratory abnormalities were also not different from those seen in other age groups.

ADVERSE REACTIONS: The following have been reported as events in clinical trials or in the routine management of patients treated with ZANTAC®. The relationship to ZANTAC therapy has been unclear in many cases. Headache, sometimes severe, seems to be related to ZANTAC administration.

Central Nervous System: Rarely, malaise, dizziness, somnolence, insomnia, and vertigo. Rare cases of reversible mental confusion, agitation, depression, and hallucinations have been reported, predominantly in severely ill elderly patients. Rare cases of reversible blurred vision suggestive of a change in accommodation have been reported.

Cardiovascular: Rare reports of tachycardia, bradycardia, and premature ventricular beats.

Gastrointestinal: Constipation, diarrhea, nausea/vomiting, and abdominal discomfort/pain.

Hepatic: In normal volunteers, SGPT values were increased to at least twice the pretreatment levels in 6 of 12 subjects receiving 100 mg qid IV for seven days, and in 4 of 24 subjects receiving 50 mg qid IV for five days. With oral administration there have been occasional reports of reversible hepatitis, hepatocellular or hepatocanalicular or mixed, with or without jaundice.

Musculoskeletal: Rare reports of arthralgias.

Hematologic: Reversible blood count changes (leukopenia, granulocytopenia, thrombocytopenia) have occurred in a few patients. Rare cases of agranulocytosis or of pancytopenia, sometimes with marrow hypoplasia, have been reported.

Endocrine: Controlled studies in animals and man have shown no stimulation of any pituitary hormone by ZANTAC and no antiandrogenic activity, and cimetidine-induced gynecomastia and impotence in hypersecretory patients have resolved when ZANTAC has been substituted. However, occasional cases of gynecomastia, impotence, and loss of libido have been reported in male patients receiving ZANTAC, but the incidence did not differ from that in the general population.

Integumentary: Rash, including rare cases suggestive of mild erythema multiforme, and, rarely, alopecia.

Other: Rare cases of hypersensitivity reactions (eg, bronchospasm, fever, rash, eosinophilia) and small increases in serum creatinine.

OVERDOSAGE: Information concerning possible overdosage and its treatment appears in the full prescribing information.

DOSAGE AND ADMINISTRATION: Active Duodenal Ulcer: The current recommended adult oral dosage is 150 mg twice daily. An alternate dosage of 300 mg once daily at bedtime can be used for patients in whom dosing convenience is important. The advantages of one treatment regimen compared to the other in a particular patient population have yet to be demonstrated.

Maintenance Therapy: The current recommended adult oral dosage is 150 mg at bedtime.

Pathological Hypersecretory Conditions (such as Zollinger-Ellison syndrome): The current recommended adult oral dosage is 150 mg twice a day. In some patients it may be necessary to administer ZANTAC® 150-mg doses more frequently. Doses should be adjusted to individual patient needs, and should continue as long as clinically indicated. Doses up to 6 g/day have been employed in patients with severe disease.

Benign Gastric Ulcer: The current recommended adult oral dosage is 150 mg twice a day.

GERD: The current recommended adult oral dosage is 150 mg twice a day.

Dosage Adjustment for Patients with Impaired Renal Function: On the basis of experience with a group of subjects with severely impaired renal function treated with ZANTAC, the recommended dosage in patients with a creatinine clearance less than 50 ml/min is 150 mg every 24 hours. Should the patient's condition require, the frequency of dosing may be increased to every 12 hours or even further with caution. Hemodialysis reduces the level of circulating ranitidine. Ideally, the dosage schedule should be adjusted so that the timing of a scheduled dose coincides with the end of hemodialysis.

HOW SUPPLIED: ZANTAC® 300 Tablets (ranitidine hydrochloride equivalent to 300 mg of ranitidine) are yellow, capsule-shaped tablets embossed with "ZANTAC 300" on one side and "Glaxo" on the other. They are available in bottles of 30 tablets (NDC 0173-0393-40) and unit dose packs of 100 tablets (NDC 0173-0393-47).

ZANTAC® 150 Tablets (ranitidine hydrochloride equivalent to 150 mg of ranitidine) are white tablets embossed with "ZANTAC 150" on one side and "Glaxo" on the other. They are available in bottles of 60 tablets (NDC 0173-0344-42) and unit dose packs of 100 tablets (NDC 0173-0344-47).

Store between 15° and 30°C (59° and 86°F) in a dry place. Protect from light. Replace cap securely after each opening.

May 1988

Glaxo Pharmaceuticals™

DIVISION OF GLAXO INC.

Research Triangle Park, NC 27709

© Copyright 1987, Glaxo Inc. All rights reserved.

ZAN517 Printed in USA September 1988

INDEX

Schlenoff, E. See Schlenoff, D. May 1988.
Schuster, DB. See Greendyke, RM. March 1988.
Schwartz, H. Speaking out. January–December 1988.
Sengbush, LR. See Job, SA. April 1988.
Servis, K. Clinical Drug Evaluation/Lovastatin. May 1988, p. 97.
Sesin, GP. Bylines from the Board/Quality assurance in the hospital environment. April 1988, p. 11.
Shaurette, GN. See Voris, JC. March 1988.
Simberkoff, MS. See Mather, SH. June 1988.
Skelton, WP. Beriberi in former POWs of the Japanese. October 1988, p. 89.
Smith, SM. See Job, SA. April 1988.
Soroff, HS. See Deysine, M. September 1988.
Steffin, JA. Bylines from the Board/Medical malpractice actions in the VA or, how to sue the government. July 1988, p. 11.
Stevens, B. See Hartmann, R. June 1988.
Stiebel, V. See Goldberg, NB. February 1988.
Stiers, W. See Budiman-Mak, E. July 1988.
Sunshine, J. Capital Comment. January–December 1988.
Suzuki, NT; Breuninger, WB. Medication refill clinic: A cost-effective alternative. April 1988, p. 57.

T

Talka, MA. See Kenny, MK. March 1988.
Talley, CH; Talley, HC. Practitioner Forum/Absenteeism: Who, what, why. September 1988, p. 15.
Talley, HC. See Talley, CH. September 1988, p. 15.
Tirone, J. See McLean, J. January 1988.
Turpin, RS. See Weaver, FM. November 1988.

V

Vasquez, J. See Goldberg, NB. February 1988.
Verstreate, S. See Greendyke, RM. March 1988.
Voris, JC; Shaurette, GN; O'Griofa, FM. Movement and behavioral side effects of ethmozin. March 1988, p. 95.
Voynick, IM. See Rosenheck, R. March 1988.
Vozak, F. See Budiman-Mak, E. July 1988.

W

Warren, WL; Bregman, JI; Findley, E. Waste management plan for VA facilities. January 1988, p. 42.
Weaver, FM; Darcy, LA; Turpin, RS. VA health care for women: Filling in the blanks. November 1988, p. 43.
Webb, D. Improving the structure of ambulatory care. April 1988, p. 39.
Welsh, JD. See Guild, RT. April 1988.
Wieland, GD. See Flyer, B. October 1988.
Wilentz, JS. See Rhyne, RR. February 1988.
Williams, AJ. See Santiago, SM. January 1988.
Wirshing, W. See Cummings, JL. February 1988.
Wisley, C. See McLean, J. January 1988.
Wong, T. Clinical Drug Evaluation/Cefuroxime axetil. November 1988, p. 89.
Worthen, DM. From physician to patient: David M. Worthen, MD. July 1988, p. 73. □